KRAS G12D Inhibitor HRS-4642 clinical trials
Also written HRS-4642.
Its developmentBy Jiangsu HengRui Medicine, step by step7 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses KRAS G12D Inhibitor HRS-4642 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KRAS G12D Inhibitor HRS-4642 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HRS-4642
- 9
Studies by the year they started
21 studies that test it; most in 2026 (9)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 5 |
| 2025 | 6 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 14
Jiangsu HengRui Medicine Co., Ltd. (4) · Shanghai Hengrui Pharmaceutical Co., Ltd. (3) · Fudan University (3) · Shanghai Zhongshan Hospital (2) · Zhejiang University (2) · Ruijin Hospital (2) · West China Hospital (1) · The Third Xiangya Hospital of Central South University (1)
Often tested with
Tested in the same studies.
Adebrelimab (7) · Gemcitabine (2) · Paclitaxel (2) · Notiretatug rezetecan (2) · Fluorouracil/Liposomal Irinotecan/Leucovorin/Oxaliplatin Regimen (1) · SHR-1701 (1) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (1) · Xelox (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 14
Studies that test KRAS G12D Inhibitor HRS-4642.
- Nov 2026Effect of Itraconazole on the Pharmacokinetics of Intravenous HRS-4642 in Healthy ParticipantsPhase 1 · The Third Xiangya Hospital of Central South University
- Dec 2026A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.Phase 2 · Shanghai Zhongshan Hospital
- Feb 2027A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy ParticipantsPhase 1 · Shanghai Hengrui Pharmaceutical Co., Ltd.
- Feb 2027HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsPhase 2 · Zhejiang University
- Mar 2027Exploratory Platform Research on Precision Therapy of Advanced Pancreatic CancerPhase 2 · Fudan University
- Mar 2027A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid TumorsPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
- Apr 2027An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic CancerPhase 2 · Shanghai Zhongshan Hospital
- May 2027HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D MutationPhase 2 · Zhejiang University
- Jun 2027HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic CancerPhase 2 · Ruijin Hospital
- Jun 2027HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic CancerPhase 2 · Ruijin Hospital
Studies
Open first, then newest update. How each study uses KRAS G12D Inhibitor HRS-4642 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy ParticipantsNot yet recruitingPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07906691Written as HRS4642
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerNot yet recruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07900789Written as HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- Effect of Itraconazole on the Pharmacokinetics of Intravenous HRS-4642 in Healthy ParticipantsNot yet recruitingPhase 1The Third Xiangya Hospital of Central South UniversityNCT07894679Written as HRS-4642
- HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic CancerRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07232875Written as HRS-4642 + AG
- An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07806058Written as HRS-717 + HRS-4642+SHR-1316;
- An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic CancerRecruitingPhase 2Shanghai Zhongshan HospitalNCT06938282Written as HRS-4642
- A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07438106Written as HRS-4642 Injection
- Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic CancerNot yet recruitingPhase 2Changhai HospitalNCT07691593Written as HRS-4642+NALIRIFOX
- HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsRecruitingPhase 2Zhejiang UniversityNCT06770452Written as HRS-4642
- HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic CancerRecruitingPhase 2Ruijin HospitalNCT06587061Written as HRS-4642+AG
- HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic CancerRecruitingPhase 2Ruijin HospitalNCT07131514Written as HRS-4642+AG +Adebrelimab
- Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2Fudan UniversityNCT06427239Written as HRS-4642
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07503639Written as HRS-4642
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D MutationRecruitingPhase 2Zhejiang UniversityNCT07240766Written as HRS-4642+AG+Nimotuzumab
- HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07296341Written as HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine
- Exploratory Platform Research on Precision Therapy of Advanced Pancreatic CancerRecruitingPhase 2Fudan UniversityNCT06547736Written as SHR-A2102, HRS4642 and Adebrelimab
- A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06520488Written as HRS-4642
- Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid TumorsNot yet recruitingPhase 1/2Henan Cancer HospitalNCT06955390Written as SHR-A2102+HRS-4642
- A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.RecruitingPhase 2Shanghai Zhongshan HospitalNCT06620848Written as HRS-4642 monotherapy
- HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 1/2West China HospitalNCT06773130Written as HRS-4642
See all 21 studies that test KRAS G12D Inhibitor HRS-4642 →
Given beside what is tested · 1 — KRAS G12D Inhibitor HRS-4642 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting1
Newly registered3
- A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy ParticipantsOct 30, 2026NCT07906691
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerOct 28, 2026NCT07900789
- Effect of Itraconazole on the Pharmacokinetics of Intravenous HRS-4642 in Healthy ParticipantsOct 26, 2026NCT07894679